ArticleThe Journal of infectious diseases2018

HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.

Yingying Dou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.